Theriva Biologics anuncia la presentación de los datos de seguridad de uso y farmacocinética de la cohorte 1 del ensayo clínico de fase 1b/2a de SYN-004 (ribaxamasa) en receptores de trasplantes alogénicos de células hematopoyéticas
February 16, 2023 12:05 ET
|
Theriva Biologics, Inc.
- Datos presentados en los Tandem Meetings 2023: Reuniones sobre trasplantes y terapias celulares de la ASTCT y el CIBMTR - - Los análisis de los pacientes que recibieron meropenem sugieren que...
Theriva Biologics Announces Presentation of Safety and Pharmacokinetic Data from Cohort 1 of the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients
February 16, 2023 12:05 ET
|
Theriva Biologics, Inc.
- Data presented at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR - - Analysis of patients receiving meropenem suggest that SYN-004 is well-tolerated...
Theriva Biologics to Participate in the B. Riley Securities 3rd Annual Oncology Conference
January 17, 2023 16:05 ET
|
Theriva Biologics, Inc.
ROCKVILLE, Md., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed to...
Theriva Biologics Announces First Patient Dosed in VIRAGE, a Phase 2b Trial of Systemically Administered VCN-01 in Combination with Chemotherapy in Pancreatic Ductal Adenocarcinoma
January 17, 2023 08:00 ET
|
Theriva Biologics, Inc.
-Initiation of Phase 2b trial follows clearance from the US Food and Drug Administration (FDA) and Spanish Agency for Medicines and Health Products (AEMPS)- -The first patient was dosed in Spain;...
Theriva Biologics Announces Dosing of First Patient in the Investigator Sponsored Phase 1 Trial of VCN-01, an Intravenous Oncolytic Adenovirus, in Patients with Brain Tumors
January 09, 2023 08:00 ET
|
Theriva Biologics, Inc.
-Clinical trial is being conducted at St. James’s University Hospital, United Kingdom, in collaboration with the University of Leeds- ROCKVILLE, Md., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Theriva...
Theriva Biologics to Participate in Upcoming Investor Conferences
December 01, 2022 08:00 ET
|
Theriva Biologics, Inc.
ROCKVILLE, Md., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed to...
Theriva Biologics Reports Third Quarter 2022 Operational Highlights and Financial Results
November 10, 2022 16:45 ET
|
Theriva Biologics, Inc.
–Reported encouraging clinical data supporting the differentiated mode-of action of Theriva’s novel oncolytic adenovirus (OV) platform– –Received clearance from the Federal Drug Administration (FDA)...
Theriva Biologics to Reschedule Conference Call and Webcast to Discuss Third Quarter 2022 Operational Highlights and Financial Results
November 10, 2022 07:00 ET
|
Theriva Biologics, Inc.
-Conference call to be held on Friday, November 11 at 8:30 a.m. ET- ROCKVILLE, Md., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a...
Theriva Biologics to Host Conference Call and Webcast to Discuss Third Quarter 2022 Operational Highlights and Financial Results
November 03, 2022 16:05 ET
|
Theriva Biologics, Inc.
ROCKVILLE, Md., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed to...
Theriva Biologics Announces First Patient Dosed in Second Cohort of Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients
November 03, 2022 08:00 ET
|
Theriva Biologics, Inc.
- Initiation of Cohort 2 Follows a Positive Review of Safety and Pharmacokinetic (PK) Data from Cohort 1 by an Independent Data and Safety Monitoring Committee - - Cohort 2 Patient Dosing Highlights...